Xenetic Biosciences, Inc. (NASDAQ:XBIO) is thrilled to announce the engagement of Scott N. Cullison as an executive consultant for business development. Mr. Cullison will be instrumental in helping to further advance the Company’s DNase-based oncology platform, which is focused on developing innovative immune-oncology technologies to fight hard-to-treat cancers.
Mr. Cullison is an expert in the pharmaceutical industry, having accumulated more than two decades of experience in business development, alliance management, commercialization, product management, R&D program team leadership, and strategic planning.
He has achieved remarkable successes, including signing multiple deals with major pharmaceutical companies, which validated scientific platforms, provided non-dilutive capital, raised capabilities, and enabled growth and value creation through private financings and IPOs. He also has broad commercial experience in primary care and specialty orphan indications for small molecules and personalized cell therapies.
Scott’s decades of experience in the pharmaceutical industry make him an invaluable addition to our team. His knowledge and skillset are perfectly suited to help us optimize our technology platforms and identify the most effective collaborations and partnerships to rapidly advance our DNase-based platform. We are thrilled to have Jeffrey Eisenberg onboard as our Chief Executive Officer and are confident that his presence will help us reach our strategic goals.
Mr. Cullison is a highly experienced executive in the biotech/pharma industry, currently serving as the Owner/Consultant for Stride BDCOM Consulting. He recently exited his role as Vice President, Business Development and Commercial Planning at Peloton Therapeutics, following the completion of a $2.2 billion acquisition by Merck. His impressive career also includes 13 years at Targacept, Inc., where he held a number of roles from Business Development Analyst to Vice President, Business Development.
Most recently, he has been leading the commercial planning activities for a late-stage gene modified T cell therapy product at Bellicum Pharmaceuticals. With his expertise, Mr. Cullison is well-equipped to provide senior executive level business development and commercial planning strategy/execution services.
Mr. Cullison has a diverse educational background, having earned a Bachelor of Science degree in Molecular & Cellular Biology from the University of Arizona and a Master of Business Administration degree from Wake Forest University’s Babcock Graduate School of Management. With this combination of scientific knowledge and business acumen, he is well-equipped to tackle any challenge that comes his way.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is revolutionizing the field of immune-oncology with its breakthrough DNase platform. By targeting neutrophil extracellular traps (NETs) involved in cancer progression and resistance to treatment, this platform has the potential to vastly improve the outcomes of existing treatments, including immunotherapies.
Xenetic is currently focused on advancing its systemic DNase program into the clinic, as an adjunctive therapy for pancreatic carcinoma and other advanced or metastatic solid tumors.
XCART™, the Company’s personalized CAR T platform technology, is revolutionizing the treatment of B-Cell lymphomas. Through its cutting-edge technology, XCART™ is able to target the unique B-Cell receptor on the surface of an individual patient’s malignant tumor cells, providing a personalized approach to combatting cancer.